Low-dose ofatumumab for rituximab-resistant nephrotic syndrome

Drug resistant idiopathic nephrotic syndrome (DRNS) remains a therapeutic dilemma. In this pilot study, the efficacy of the new fully humanised, anti-CD20 monoclonal antibody ofatumumab was tested in 4 children with persistence of proteinuria for at least 12 months in spite of a full drug approach (...

Full description

Saved in:
Bibliographic Details
Published in:BMJ Case Rep
Main Authors: Bonanni, Alice, Rossi, Roberta, Murtas, Corrado, Ghiggeri, Gian Marco
Format: Artigo
Language:Inglês
Published: BMJ Publishing Group 2015
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4577716/
https://ncbi.nlm.nih.gov/pubmed/26376698
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2015-210208
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items